Appendix: Key Information on Newly Approved AML Drugs
Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-C
Ballad Health, Johnson City, Tennessee, and MD Anderson Cancer Center, Houston, Texas
Dr. Nix has served on the speakers bureau for Coherus BioSciences and advisory boards for Bristol-Myers Squibb, Genentech, Puma, Sandoz, and Teva. Ms. Price has served as a consultant for Agios and on an advisory board for Daiichi Sankyo.
Allyson Price, MPAS, PA-C, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: email@example.com
J Adv Pract Oncol 2019;10(suppl 4):23–29 |
© 2019 Harborside™
This article is a part of a JADPRO certified supplement, Optimizing Treatment and Improving Outcomes for Patients With Acute Myeloid Leukemia: A Guide for Advanced Practitioners
Table of Contents
- Acute Myeloid Leukemia: An Ever-Changing Disease
- Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
- The Role of the Advanced Practitioner in Enhancing Outcomes
- Appendix: Key Information on Newly Approved AML Drugs (current article)
How to Earn Credit
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.
For access to the full length article, please sign in